ISLMF (InSilico Medicine Cayman TopCo) EBIT: $-352.05 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISLMF InSilico Medicine Cayman TopCo ISLMF
13 GF Score
Price $6.11
! 3 Warning Signs
View Full Analysis

What is InSilico Medicine Cayman TopCo EBIT?

InSilico Medicine Cayman TopCo ISLMF -1.77% 13 EBIT is $-352.05 Mil as of Dec. 2025. GuruFocus rates ISLMF with a GF Score™ of 13/100. The stock has 3 warning signs investors should review.

InSilico Medicine Cayman TopCo's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was $-332.97 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-352.05 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. InSilico Medicine Cayman TopCo's annualized ROC % for the quarter that ended in Dec. 2025 was -33.06%. InSilico Medicine Cayman TopCo's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -9,933.84%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. InSilico Medicine Cayman TopCo's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -12.06%.

InSilico Medicine Cayman TopCo  (OTCPK:ISLMF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

InSilico Medicine Cayman TopCo's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-157.056 * ( 1 - 0% )/( (916.459 + 33.677)/ 2 )
=-157.056/475.068
=-33.06 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=241.311 - 17.145 - ( 212.63 - max(0, 917.907 - 225.614+212.63))
=916.459

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=489.983 - 15.921 - ( 447.271 - max(0, 33.893 - 474.278+447.271))
=33.677

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

InSilico Medicine Cayman TopCo's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1331.88/( ( (13.647 + max(-902.836, 0)) + (13.168 + max(-5.264, 0)) )/ 2 )
=-1331.88/( ( 13.647 + 13.168 )/ 2 )
=-1331.88/13.4075
=-9,933.84 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.617 + 0 + 7.277) - (17.145 + 0 + 898.585)
=-902.836

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(21.284 + 0 + 5.45) - (15.921 + 0 + 16.077)
=-5.264

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

InSilico Medicine Cayman TopCo's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-352.047/2918.408
=-12.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InSilico Medicine Cayman TopCo EBIT Related Terms

InSilico Medicine Cayman TopCo EBIT Historical Data

* Premium members only.

The historical data trend for InSilico Medicine Cayman TopCo's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InSilico Medicine Cayman TopCo EBIT Chart

InSilico Medicine Cayman TopCo Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBIT
-221.72 -211.46 -16.84 -352.05

InSilico Medicine Cayman TopCo Quarterly Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial 0.00 8.12 -24.96 -19.08 -332.97

ISLMF vs : EBIT Comparison

For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InSilico Medicine Cayman TopCo EV-to-EBIT vs Software Industry

For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where InSilico Medicine Cayman TopCo's EV-to-EBIT falls into.


ISLMF
13GF Score
InSilico Medicine Cayman TopCo ISLMF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InSilico Medicine Cayman TopCo EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-352.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-352.05 Mil mean?
InSilico Medicine Cayman TopCo (ISLMF) has a EBIT of $-352.05 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on InSilico Medicine Cayman TopCo.
Is InSilico Medicine Cayman TopCo's EBIT too high?
InSilico Medicine Cayman TopCo's current EBIT is $-352.05 Mil. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's EBIT compare to ?
InSilico Medicine Cayman TopCo's EBIT of $-352.05 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Software company?
A good EBIT depends on the Software industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on InSilico Medicine Cayman TopCo. InSilico Medicine Cayman TopCo's current EBIT is $-352.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (ISLMF) has a current EBIT of $-352.05 Mil. The current EBIT is $-352.05 Mil. InSilico Medicine Cayman TopCo's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (ISLMF), the current EBIT is $-352.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InSilico Medicine Cayman TopCo Business Description

Comparable Companies
Other Exchanges 03696:Hong KongO15:Germany
Address Hong Kong Science Park, Unit 310, 3rd Floor, Building 8W, Phase 2, Pak Shek Kok, New Territories, Hong Kong, HKG
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
13GF Score

Get the complete analysis for ISLMF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.11
Price